Swiss Laboratory for Doping Analyses Report issue

Government

Organization Overview

First Clinical Trial
2014
NCT02423135
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Other Trials (1)

autologous blood (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1